Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price traded up 6.9% on Thursday . The stock traded as high as $20.51 and last traded at $20.28. 850,206 shares were traded during mid-day trading, an increase of 24% from the average session volume of 687,433 shares. The stock had previously closed at $18.97.
Several equities analysts have recently weighed in on the company. BidaskClub cut Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. Stifel Nicolaus restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday. TheStreet upgraded Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, October 26th. Citigroup lifted their price target on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, October 16th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a report on Friday, October 12th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $26.86.
The firm has a market capitalization of $1.02 billion, a P/E ratio of -57.94 and a beta of 0.53.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.14. The firm had revenue of $47.40 million during the quarter, compared to the consensus estimate of $47.28 million. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. The business’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period last year, the business posted $0.03 earnings per share. Research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.04 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of the business. Metropolitan Life Insurance Co. NY lifted its position in Vanda Pharmaceuticals by 18.4% during the second quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 2,671 shares during the last quarter. Allianz Asset Management GmbH raised its position in shares of Vanda Pharmaceuticals by 2.9% in the first quarter. Allianz Asset Management GmbH now owns 136,218 shares of the biopharmaceutical company’s stock valued at $2,295,000 after buying an additional 3,903 shares in the last quarter. MetLife Investment Advisors LLC raised its position in shares of Vanda Pharmaceuticals by 20.0% in the second quarter. MetLife Investment Advisors LLC now owns 24,336 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 4,063 shares in the last quarter. Strs Ohio raised its position in shares of Vanda Pharmaceuticals by 9.7% in the second quarter. Strs Ohio now owns 47,500 shares of the biopharmaceutical company’s stock valued at $904,000 after buying an additional 4,200 shares in the last quarter. Finally, Fox Run Management L.L.C. raised its position in shares of Vanda Pharmaceuticals by 23.9% in the second quarter. Fox Run Management L.L.C. now owns 28,611 shares of the biopharmaceutical company’s stock valued at $545,000 after buying an additional 5,516 shares in the last quarter. Hedge funds and other institutional investors own 93.54% of the company’s stock.
Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Featured Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.